12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Company News  |  Other News

Shire, Teva neurology news

Shire and Teva settled litigation filed by Shire in 2010 in the U.S. District Court for the District of Delaware alleging Teva's ANDA submission for a generic version of ADHD drug Intuniv guanfacine infringed Shire's U.S. Patent Nos. 6,287,599 and 6,811,794. The patents cover sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles. The '599...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >